DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update. Instil has entered into an agreement with a collaborator that has a successful track record of manufacturing and dosing patients with cell therapies to conduct preclinical manufacturing feasibility studies in the ITIL-306 program.

达拉斯，2024年1月16日（环球通讯社）--Instil Bio，Inc.（“Instil”或“公司”）（纳斯达克：TIL），一家临床阶段的生物制药公司，专注于开发肿瘤浸润淋巴细胞，或TIL，治疗癌症患者的疗法，今天宣布了一项战略更新。Instil已与合作者达成协议，该合作者在制造和给患者服用细胞疗法方面有成功的记录，可以在ITIL-306计划中进行临床前制造可行性研究。

The feasibility studies have been initiated, and if the feasibility studies are successful, Instil’s collaborator may open an investigator-initiated clinical trial (IIT) to enroll patients with non-small cell lung cancer (NSCLC) in China. In the event the IIT generates compelling proof-of-concept clinical data in 2024, Instil may explore options for a potential transition of ITIL-306 to a US-based CDMO for manufacturing and clinical development primarily at US clinical trial sites.

可行性研究已经启动，如果可行性研究成功，Instil的合作者可能会在中国开展一项由研究者发起的临床试验（IIT），以招募非小细胞肺癌（NSCLC）患者。如果IIT在2024年产生令人信服的概念验证临床数据，Instil可能会探索ITIL-306向美国CDMO潜在过渡的选择，主要用于美国临床试验地点的制造和临床开发。

With the objective of saving costs and improving time efficiency, the Company is announcing the closure of its UK manufacturing and clinical operations, thereby reducing its UK workforce which is expected to be substantially completed by the first half of 2024. Instil plans to retain key process development, research, and related personnel to advance early-stage pipeline development of CoStAR™ and other novel TIL technologies, and to support the company’s collaboration.

为了节省成本和提高时间效率，该公司宣布关闭其英国制造和临床业务，从而减少其英国劳动力，预计将在2024年上半年基本完成。Instil计划保留关键流程开发、研究和相关人员，以推进CoStAR的早期管道开发™ 和其他新颖的TIL技术，并支持公司的合作。

About Instil Bio Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing TIL therapies for the treatment of patients with cancer. Instil has assembled an accomplished management team with a successful track record in the research, development and manufacture of cell .

关于Instil Bio Instil Bio，Inc.（纳斯达克：TIL）是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的TIL疗法。Instil已经组建了一支成熟的管理团队，在cell的研究、开发和制造方面取得了成功。